2190 (2190) Fair Value & Analysis

Healthcare · Market cap HK$6.3B

2 2190 2190 · HK

PriceHK$18.99

Fair ValueHK$13.49

Upside-29.0%

Quality68/100

Watch 2190 for free — get notified when fair value or trend changes. Watch for free

Evidence: High Range HK$10.52 – HK$16.47

Fair value as of: Jul 2, 2026

From 26 valuation models · updated today

Share price −6.8% over the past month.

Price vs Fair Value (12 months)

12‑month range HK$17.35 – HK$27.17 · fair‑value band HK$10.52 – HK$16.47 · the HK$18.99 price screens above the HK$13.49 fair value. As of Jul 2, 2026.

✦ Which stocks are undervalued right now? Check free Discover now →

Analysis

2190 (2190) currently trades at HK$18.99, while our model-based Fair Value estimate is HK$13.49 — implying the stock looks roughly 29.0% overvalued today. We read business quality at 68/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).

Over the trailing twelve months, 2190 generated revenue of HK$1.1B at a net margin of 23.1%. Revenue grew 38.2% year over year. It earns a return on equity of 7.7%. The balance sheet holds a net cash position of HK$516M. Fundamentals as of Jul 2, 2026

Key figures & financial health

Revenue (TTM) HK$1.1B

Revenue growth (YoY) +38.2%

Net margin 23.1%

Return on equity 7.7%

Free cash flow HK$269M FY2025

P/E ratio 21.8

More key figures

Operating margin 21.7%

EPS (TTM) HK$0.3700

Dividend yield 1.2%

EPS growth (YoY) +302%

Net cash HK$516M FY2025

Figures from reported company fundamentals (EODHD) · as of Jul 2, 2026. TTM = trailing twelve months.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

2190 reported revenue of HK$1.1B in FY2025 versus HK$178M in FY2021, a compound +56.1%/yr. Reported net income was HK$244M in FY2025.

Revenue +56.1%/yr

FY21 HK$178M

FY22 HK$334M

FY23 HK$528M

FY24 HK$782M

FY25 HK$1.1B

Net income

FY21 −HK$200M

FY22 −HK$114M

FY23 −HK$78.7M

FY24 HK$100M

FY25 HK$244M

Is 2190 fairly valued? → Check now

Similar stocks

6 more Medical Devices stocks, each showing price versus our Fair Value estimate (as of Jul 2, 2026).

Stock	Price	Fair Value	vs Fair Value
ABT ABT	1,600 MXN	1,231 MXN	-23%
Abbott Laboratories, ABTT34	R$39.41	R$30.42	-23%
Stryker Corporation S1YK34	R$79.21	R$43.74	-45%
Medtronic plc MDT	$81.67	$60.02	-27%
Boston Scientific Corporation B1SX34	R$229.30	R$43.33	-81%
Edwards Lifesciences Corporation EW	$85.98	$41.02	-52%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks Technology Financial Services Healthcare Consumer Cyclical Consumer Defensive Communication Services Industrials Energy Basic Materials Real Estate Utilities Deeply Undervalued Stocks Undervalued Blue-Chip Stocks Undervalued Small-Cap Stocks

Frequently asked questions

Is 2190 (2190) undervalued?

As of Jul 2, 2026, our model estimates a fair value of HK$13.49 versus a price of HK$18.99 — about −29% (overvalued). Model-based estimate, not financial advice.

What is the fair value of 2190?

Our model-based fair value for 2190 is HK$13.49 (as of Jul 2, 2026), built from audited fundamentals. The current price is HK$18.99.

What is the quality score of 2190?

2190 has a Quality Score of 68/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

What is the revenue of 2190 (2190)?

2190 reported trailing-twelve-month revenue of about HK$1.1B (latest available figure, as of Jul 2, 2026).

What is the net profit margin of 2190?

The net profit margin of 2190 is about 23.1%, meaning it keeps roughly 23.1% of revenue as net income. Based on the latest reported figures.

Does 2190 pay a dividend?

2190 currently shows a dividend yield of about 1.21% relative to its recent price (as of Jul 2, 2026).

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.